Cyclosporine induces the expression of the cyclin inhibitor p21

A K Khanna1, J D Hosenpud

  • 1Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee 53226, USA. akkhanna@mcw.edu

Transplantation
|May 26, 1999
PubMed
Abstract

Insights

Cyclosporine A (CsA) suppresses T cell proliferation by increasing the cell cycle inhibitor p21, a process dependent on transforming growth factor-beta (TGF-beta). Inducing p21 independently of TGF-beta may reduce immunosuppression toxicity.

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Current immunosuppression targets T cell activation and proliferation.
  • Cyclosporine A (CsA) is an immunosuppressant.
  • Cell cycle progression involves cyclins and cyclin-dependent kinases.

Purpose of the Study:

  • To investigate if CsA suppresses cell cycle progression via p21 induction.
  • To determine if CsA's p21 induction is dependent on transforming growth factor-beta (TGF-beta).

Main Methods:

  • Reverse transcription PCR and Western blot to assess p21 mRNA and protein.
  • Luciferase assay to study p21 promoter activity.
  • Use of anti-TGF-beta antibody and TGF-beta altered cells to assess dependence.

Main Results:

  • CsA induced p21 mRNA, protein expression, and promoter activity in T cells and A-549 cells.
  • CsA's induction of p21 was inhibited by anti-TGF-beta antibody.
  • Effects on p21 required TGF-beta, as shown in TGF-beta altered cells.

Conclusions:

  • CsA's antiproliferative effects involve p21 induction, which is dependent on TGF-beta.
  • Inducing p21 independently of TGF-beta could mitigate immunosuppression toxicity.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...